Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Biotechnology

Healthcare
$19.17 -1.71%

-$0.22 today

Market cap
$676.80M
Beta
1.08
P/E (TTM)
-36.5
EPS (TTM)
-$0.24
52W Low $7.59High $14.24

Volume 0.00M

Average 0.00M

FRX.TO Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Fennec Pharmaceuticals Inc.TSX: FRX.TO

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q1 FY2026 operating expenses of $14.62M rose 59.1% year over year, ahead of the +33.6% change in trailing-twelve-month operating expenses. Sequentially, it fell 4.2% from the prior quarter. Over 3 fiscal years it compounded at +25.2% a year.

Context

  • Operating expenses amounted to 105.8% of revenue in FY2025, up 17.9 pp from a year earlier.
  • Operating expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +59.1% holds above the trailing-twelve-month pace of +33.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14.62M-4.2% QoQ
Last fiscal yearDec 2025
$47.22M+13.0% YoY
LTMMar 2026
$53.29M+33.6% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+59.1%——
1 year+13.0%——
3-year CAGR+25.2%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
47.22M USD
Year-over-year change
+13.0%
4-year CAGR
+28.7%

Operating Expenses vs competitors

How FRX.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +33.6% is the 2nd highest of 8, against a peer median of -18.5%.
  • Operating expenses amounts to 104.1% of revenue for FRX.TO, versus a peer median of 35.9%.
FRX.TO Competitors
Operating Expenses for FRX.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$160.3M CAD-18.5%-21.7%51.6%
DR.TOMedical Facilities CorporationLTM Mar 2026$109.68M USD-23.5%-40.9%35.9%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$97.47M CAD+11.9%—35.5%
TSND.TOTerrAscend Corp.LTM Mar 2026$89.4M USD-44.2%-16.5%34.2%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$53.29M USD+33.6%+25.2%104.1%
PRN.TOProfound Medical Corp.LTM Mar 2026$51.32M USD+15.7%+18.0%273.6%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$47.09M USD+71.8%+18.5%—
HBP.TOHelix BioPharma Corp.LTM Apr 2026CA$3.3M CAD-66.1%-3.6%—
Peer median (excluding FRX.TO) —-18.5%-10.0%35.9%

Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.54M21.25M47.54M44.64M
Cost of Revenue086K1.26M3.18M3.76M
Gross Profit01.45M19.99M44.35M40.88M
Gross Margin—94.4%94.1%93.3%91.6%
Research & Development4.98M3.53M56K307K254.38K
Selling, General & Admin12.24M20.51M32.71M41.48M46.91M
Operating Expenses17.22M24.04M32.76M41.79M47.22M
Depreciation & Amortization17.22M149K287K800K103K
EBITDA(17.19M)(22.74M)(12.65M)4.8M(7.45M)
EBITDA Margin—-1481.2%-59.5%10.1%-16.7%
Operating Income(17.22M)(22.59M)(12.77M)2.57M(6.35M)
Operating Margin—-1471.6%-60.1%5.4%-14.2%
Interest Income54K195K441K1.68M800.78K
Interest Expense126K978K3.39M4.07M2.18M
Other Income / Expenses(123K)(1.13M)(3.27M)(2.64M)(3.29M)
Income Before Tax(17.35M)(23.71M)(16.05M)(71K)(9.64M)
Pre-Tax Margin—-1544.9%-75.5%-0.1%-21.6%
Income Tax Expense110K147K0365K106K
Net Income(17.46M)(23.86M)(16.05M)(436K)(9.74M)
Net Margin—-1554.5%-75.5%-0.9%-21.8%
EPS (Basic)(0.67)(0.91)(0.60)(0.02)(0.34)
EPS (Diluted)(0.67)(0.91)(0.60)(0.02)(0.34)
Weighted Avg Shares25.89M26.28M26.57M21.8M28.58M
Weighted Avg Shares (Diluted)26.01M26.28M26.57M27.3M28.58M

Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$19.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.